Please use this identifier to cite or link to this item:
|Title:||Secretory phospholipase: a potential target for cardiovascular therapies|
|Citation:||Heart and metabolism : management of the coronary patient, 2013; 60(60):22-26|
|Publisher:||Les Laboratoires Servier|
|Stephen J. Nicholls, MyNgan Duong|
|Abstract:||Increasing evidence implicates the activation of inflammatory pathways in the pathogenesis of cardiovascular disease. Accordingly, there is considerable interest in the development of new cardioprotective therapies that target inflammatory factors that promote the progression of heart disease. Secretory phospholipase A 2 (sPLA 2 ) generates a range of fatty acid and prostaglandin metabolites that play a pivotal role in the molecular events involved in the formation, progression and rupture of atherosclerotic plaque. The findings of sPLA 2 in atherosclerotic plaque, accelerated disease in transgenic models and association between elevated sPLA 2 levels in plasma and adverse cardiovascular events in population studies suggest that the pharmacological inhibition of sPLA 2 may be beneficial. The early experience with the clinical development of sPLA 2 inhibitors to reduce cardiovascular risk will be reviewed.|
|Keywords:||Cardiovascular disease; inflammation; risk factor; sPLA₂|
|Rights:||Copyright status unknown|
|Appears in Collections:||Aurora harvest 3|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.